Table 2.
Percent total fatty acid contenta
| Fatty Acids | BT-474 Breast | A549 Lung | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| EtOH | 100 μM LA | 100 μM DHA | EtOH | 100 μM LA | 100 μM DHA | |
| 16:1 - Ptlmitic n-7 | 10.3 ± 3 2 | 7.5 ± 3.1 | 3.6 ± 0.3 | 4.9 ± 0.8 | 2.7 ± 1.1 | 4.8 ± 2.9 |
| 18:0 - Srearic | 24.3 ± 2.5 | 21.6 ± 1.4 | 15.7 ± 3.4 | 21.1 ± 3.0 | 13.6 ± 0.5 | 15.3 ± 2.3 |
| 18:1 - Oleic n-9 | 42.5 ± 4.1 | 22.1 ± 3.9 | 18.1 ± 4.5 | 38.3 ± 1.3 | 22.1 ± 0.5 | 22.0 ± 2.9 |
| 18:2 - Linoleic n-6 | 17.0 ± 1.0 | 46.7 ± 4.4 | 9.2 ± 2.8 | 3.8 ± 0.8 | 38.6 ± 1.2 | 4.1 ± 0.9 |
| 18.3 - Linolenic n-3 | 0.3 ± 0.6 | 0.2 ± 0.2 | 1.4 ± 1.9 | 0.0 ± 0.0 | 0.2 0.1 | 1.4 ± 2.4 |
| 20:1 - Eicosenoic n-9 | 1.1 ± 1.7 | 0.3 ± 0.0 | 1.0 ± 1.6 | 0.5 ± 0.1 | 0.4 ± 0.1 | 3.1 ± 1.1 |
| 20:2 - Eicosadienoic n-6 | 0.9 ± 0.6 | 0.0 ± 0.0 | 0.4 ± 0.7 | 0.9 ± 0.1 | 0.9 ± 0.5 | 2.0 ± 1.2 |
| 20:3 - Eicostrienoic n-3 | 0.8 ± 0.2 | 0.0 ± 0.0 | 0.3 ± 0.3 | 0.8 ± 0.3 | 0.4 0.4 | 1.5 ± 0.8 |
| 20:4 - Arachidonic n-6 | 2.5 ± 0.3 | 1.6 ± 0.2 | 1.8 ± 0.3 | 24.5 ± 1.8 | 17.8 ± 1.7 | 8.5 ± 0.5 |
| 20:5 - EPA n-3 | 0.1 ± 0.1 | 0.0 ± 0.0 | 4.3 ± 1.4 | 1.1 ± 0.3 | 0.8 0.5 | 3.8 ± 0.6 |
| 22:6 - DHA n-3 | 0.2 ± 0.1 | 0.0 ± 0.0 | 4.3 ± 1.4 | 1.1 ± 0.3 | 2.4 ± 0.1 | 33.5 ± 5.8 |
|
| ||||||
| %Total n-6 | 20.4 | 48.4 | 11.4 | 29.3 | 57.4 | 14.3 |
| %Total n-3 | 1.5 | 0.2 | 50.2 | 6.0 | 3.8 | 40.2 |
a
Abbreviations are as follows: EtOH, ethanol; LA linoleic acid; DHA, docosahexaenoic acid. Results are presented as percentage total fatty acid ± SD (n=3) for BT-474 human breast ductal carcinoma and A549 human lung adenocarcinoma. Cells were treated with 100 μM PUFA FAME for 48 hours before being resolved by gas chromatography. Additionally, total n-6 and n-3 PUFA content is listed for each treatment and cell line.